Trial Profile
A Multi-Center, Randomized, Phase 3 Study of Adjuvant Oncophage® Versus Observation in Patients With High Risk After Surgical Treatment for Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2016
Price :
$35
*
At a glance
- Drugs Vitespen (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Agenus
- 07 Dec 2016 New trial record